Salem Billan

TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.

TL;DR: It is shown that an array of sensors based on gold nanoparticles can rapidly distinguish the breath of lung cancer patients from the Breath of healthy individuals in an atmosphere of high humidity.

TL;DR: The results showed that the nanosensor array could differentiate between ‘healthy’ and ‘cancerous’ breath, and between the breath of patients having different cancer types, and could lead to the development of an inexpensive, easy-to-use, portable, non-invasive tool that overcomes many of the deficiencies associated with the currently available diagnostic methods for cancer.

TL;DR: The presented results could lead to the development of a cost-effective, fast, and reliable method for the differential diagnosis of HNC that is based on breath testing with an NA-NOSE, with a future potential as screening tool.

TL;DR: Checkpoint inhibitors such as anti- PD-1 and anti-PD-L1 antibodies, were shown to significantly improve disease free survival and overall survival after failure of platinum-based chemotherapy, and expression of HPV is associated with better response to single modality treatment and improved survival.